Press releases prior to August 2023 are from EIP Pharma, Inc., a wholly-owned subsidiary of CervoMed, Inc.

CervoMed to Participate in Upcoming Investor Conferences
BOSTON , Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s management will participate in the following investor conferences during the month of
August 27, 2024
PDF Version
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB – - AscenD-LB Phase 2a results demonstrated neflamapimod
July 29, 2024
PDF Version
CervoMed to Participate in the Emerging Growth Conference
BOSTON , July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will present virtually at the Emerging Growth Conference .
July 17, 2024
PDF Version
Displaying 11 - 20 of 32